CO2022000751A2 - Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo - Google Patents

Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo

Info

Publication number
CO2022000751A2
CO2022000751A2 CONC2022/0000751A CO2022000751A CO2022000751A2 CO 2022000751 A2 CO2022000751 A2 CO 2022000751A2 CO 2022000751 A CO2022000751 A CO 2022000751A CO 2022000751 A2 CO2022000751 A2 CO 2022000751A2
Authority
CO
Colombia
Prior art keywords
pyrazolone
preparation
pyrimidine compound
compound
present
Prior art date
Application number
CONC2022/0000751A
Other languages
English (en)
Inventor
Qian Wang
Sijie Shu
Guangxin Xia
Hui Ge
Bingbin Zhang
Guoyong Huo
Lin Zhang
Chen Shi
Jiangsong Lou
Chi Zhang
Zhihui Zhang
Yu Mao
Jianxin Yu
Ying Ke
Yanjun Liu
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of CO2022000751A2 publication Critical patent/CO2022000751A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente invención se describen un compuesto de pirazolona y pirimidina, y un método de preparación y un uso del mismo. En la presente invención se proporciona un compuesto de pirazolona y pirimidina como en la fórmula (I), teniendo dicho compuesto una mejor actividad inhibidora de la quinasa WEE1.
CONC2022/0000751A 2019-06-28 2022-01-27 Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo CO2022000751A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910578299 2019-06-28
PCT/CN2020/112034 WO2020259724A2 (zh) 2019-06-28 2020-08-28 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Publications (1)

Publication Number Publication Date
CO2022000751A2 true CO2022000751A2 (es) 2022-04-29

Family

ID=73889014

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000751A CO2022000751A2 (es) 2019-06-28 2022-01-27 Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo

Country Status (13)

Country Link
US (1) US20220324868A1 (es)
EP (1) EP4008719A4 (es)
JP (1) JP2022539460A (es)
KR (1) KR20230046270A (es)
CN (1) CN112142748B (es)
AU (1) AU2020304472A1 (es)
BR (1) BR112021026620A2 (es)
CA (1) CA3145348A1 (es)
CL (1) CL2021003498A1 (es)
CO (1) CO2022000751A2 (es)
IL (1) IL289395A (es)
MX (1) MX2022000199A (es)
WO (1) WO2020259724A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302171A (en) 2018-03-09 2023-06-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3H-pyrazolo[4,3-D]pyrimidine-3-ones
CN115867551A (zh) * 2020-05-15 2023-03-28 里科瑞尔姆Ip控股有限责任公司 单一疗法和组合疗法
CN114591334B (zh) * 2020-12-04 2023-10-20 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
WO2022251224A1 (en) * 2021-05-28 2022-12-01 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
AU2022384370A1 (en) * 2021-11-09 2024-06-13 Hangzhou Glubio Pharmaceutical Co. Ltd. Wee1 protein kinase degradation agent and use thereof
WO2023193789A1 (en) * 2022-04-08 2023-10-12 Beijing Neox Biotech Limited Wee1 degrading compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1523485B1 (en) 2002-07-15 2007-02-14 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP2010522188A (ja) 2007-03-20 2010-07-01 スミスクライン ビーチャム コーポレーション 化合物
CN101677554A (zh) 2007-03-20 2010-03-24 史密丝克莱恩比彻姆公司 化合物
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
JP2012518598A (ja) 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
JP6717457B2 (ja) * 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
AU2018312448B2 (en) * 2017-08-01 2022-09-15 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN109810111B (zh) * 2017-11-20 2023-10-27 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
IL302171A (en) * 2018-03-09 2023-06-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3H-pyrazolo[4,3-D]pyrimidine-3-ones

Also Published As

Publication number Publication date
CL2021003498A1 (es) 2022-08-19
EP4008719A4 (en) 2023-03-22
CA3145348A1 (en) 2020-12-30
JP2022539460A (ja) 2022-09-09
EP4008719A2 (en) 2022-06-08
KR20230046270A (ko) 2023-04-05
IL289395A (en) 2022-02-01
WO2020259724A2 (zh) 2020-12-30
BR112021026620A2 (pt) 2022-06-07
WO2020259724A3 (zh) 2021-02-18
MX2022000199A (es) 2022-09-29
AU2020304472A1 (en) 2022-03-03
US20220324868A1 (en) 2022-10-13
CN112142748B (zh) 2023-07-04
CN112142748A (zh) 2020-12-29

Similar Documents

Publication Publication Date Title
CO2022000751A2 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
ECSP22012826A (es) Inhibidores de parp1
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MA40239B1 (fr) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanopyrido[1',2':4,5]pyrazino[2,1-b]oxazépin-8-olate de sodium
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
CL2020003083A1 (es) Inhibidores de masp-2 y métodos de uso
TR201902525T4 (tr) Janus ile alakalı kinazların (jak) inhibitörleri olarak bir veya daha fazla ilave ajan ile pirolo [2,3-d]pirimidin türevlerinin kombinasyonu.
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
PE20240651A1 (es) Sintesis de indazoles
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
MX2022000243A (es) Nuevos compuestos heterociclicos.
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CO2018008253A2 (es) Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina
CO2022000748A2 (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones
NZ745474A (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof